B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.